LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients

Contributed by: Business Wire

Logo

Tags

Medical Devices

FDA

Health

Clinical Trials

Optical

Biotechnology

FDA Review

More Like This

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement

PR Newswire associated0

LUMA Vision Receives FDA Clearance for VERAFEYE 2D/4D Cardiac Visualization Platform

LUMA Vision Co-Founders, CEO Fionn Lahart (right) and Chief Technology Officer Christoph Hennersperger (left). (Photo: Business Wire)

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy